A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Study Details
Study Description
Brief Summary
This trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
The primary objective is to choose a dose for further investigation by assessing the effect of pegloticase 16 mg dose with a possibility of potential additional dose level between 24 mg and 32 mg administered via IV Q4 Wks, co-administered with weekly doses of oral MTX, as measured by the sustained normalization of serum uric acid (sUA) to <6 mg/dL for at least 80% of the time during Month 6 and the duration of sUA to <6 mg/dL over 24 week treatment period in adult participants with chronic gout refractory to conventional therapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Pegloticase 16mg cohort 16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly |
Biological: Pegloticase and Methotrexate (MTX)
16 mg IV dose of pegloticase q4 weeks co-administered with 15 mg oral dose methotrexate weekly
|
| Experimental: Pegloticase 24/32mg cohort 24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly |
Biological: Pegloticase and Methotrexate (MTX)
Potential higher IV dose of pegloticase (between 24-32 mg) q4 weeks co-administered with 15 mg oral dose methotrexate weekly and/or potential reduction of infusion duration
|
Outcome Measures
Primary Outcome Measures
- Participants achieving and maintaining serum uric acid (sUA) concentration <6 mg/dL for at least 80% of the time [Month 6]
Proportion of responders at Month 6 (Weeks 20, 21, 22, 23 and 24), defined as subjects achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 6
- Total duration of sUA concentration <6 mg/dL [Week 24]
Time to first sUA ≥6 mg/dL after first achieving sUA <6 mg/dL, from the first pegloticase infusion until Week 24
Secondary Outcome Measures
- Pharmacokinetic parameters (e.g., AUC, Cmax and Ctrough) [Baseline to 24 months]
- Proportion of subjects with pre-infusion sUA <6 mg/dL at each scheduled visit [Baseline to 25 months]
- Area under the sUA concentration vs time curve from Day 1 to Week 24 and Day 1 to Week 48 [Day 1 to Week 24 and Day 1 to Week 48]
- Proportion of the subjects sustained sUA< 6 mg/dL from Day 1 to Week 24 and Day 1 to Week 48 [Day 1 to Week 24 and Day 1 to Week 48]
- Proportion of subjects with anti-uricase antibodies and the proportion of subjects with anti-poly (ethylene glycol) antibodies and their titers at each scheduled visit [Baseline to 24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and able to give informed consent.
-
Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
-
Adult men or women ≥18 and <80 years of age.
-
Uncontrolled gout, defined as meeting the following criteria:
-
Hyperuricemia during the screening period defined as sUA ≥6 mg/dL, and;
-
Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a contraindication to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;
-
Symptoms of gout including at least 1 of the following:
-
Presence of at least one tophus
-
Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
-
Presence of chronic gouty arthritis as evidenced by either clinical signs consistent with chronic synovitis on clinical examination or the presence of typical gouty erosion(s) on hand and/or foot X-rays
-
Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -4 and remain off while receiving pegloticase treatments.
-
Women of childbearing potential (including those with an onset of menopause <2 years prior to screening, non-therapy-induced amenorrhea for <12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -4; subjects must agree to use 2 reliable forms of contraception during the trial, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -4 (start of MTX) and continue for 4 weeks/30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX (whichever is the longest duration after the last dose of pegloticase or MTX). Highly effective contraceptive methods (with a failure rate <1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
-
Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of reproductive potential during the trial, beginning with the initiation of MTX at Week -4 and continuing and for at least 3 months after the last dose of MTX.
-
Able to tolerate MTX 15 mg orally for 4 weeks (Week -4 through Day 1) prior to enrollment.
Exclusion Criteria:
-
Weight >160 kg (352 pounds) at Screening.
-
Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Day 1 Visit.
-
Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
-
Current or chronic treatment with systemic immunosuppressive agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other corticosteroid on a chronic basis (3 months or longer) would also meet exclusion criteria.
-
History of any transplant surgery requiring maintenance immunosuppressive therapy.
-
Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA positivity.
-
Known history of hepatitis C virus RNA positivity, unless treated and viral load is negative.
-
Known history of Human Immunodeficiency Virus (HIV) positivity.
-
Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit centrally or locally).
-
Chronic renal impairment defined as estimated glomerular filtration rate (eGFR) <40 mL/min/1.73 m^2 or currently on dialysis.
-
Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to enrollment at Day 1.
-
Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of birth control, as determined by the Investigator.
-
Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
-
Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
-
Contraindication to MTX treatment or MTX treatment considered inappropriate.
-
Known intolerance to MTX.
-
Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -4 or plans to take an investigational drug during the trial.
-
Liver transaminase levels (AST or ALT) > 1.25 X upper limit of normal (ULN) or albumin < the lower limit of normal (LLN) at the Screening Visit.
-
Chronic liver disease.
-
White blood cell count <4000/µl, hematocrit <32 percent, or platelet count <75,000/µl.
-
Currently receiving systemic or radiologic treatment for ongoing cancer, excluding non-melanoma skin cancer.
-
History of malignancy within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
-
Diagnosis of osteomyelitis.
-
Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
-
Unsuitable candidate for the trial, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the trial.
-
Alcohol use in excess of 3 alcoholic beverages per week.
-
A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e., subject must be able to tolerate at least one: colchicine and/or non-steroidal anti-inflammatory drugs and/or low dose prednisone ≤10 mg/day).
-
Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Orthopedic Physicians Alaska | Anchorage | Alaska | United States | 99508 |
| 2 | Arizona Arthritis & Rheumatology Research, PLLC | Glendale | Arizona | United States | 85306 |
| 3 | East Bay Rheumatology Medical Group, Inc. | San Leandro | California | United States | 94578 |
| 4 | ProHealth Research Center | Doral | Florida | United States | 33166 |
| 5 | Napa Research Center | Pompano Beach | Florida | United States | 33064 |
| 6 | GCP Clinical Research | Tampa | Florida | United States | 33064 |
| 7 | The Center for Rheumatology and Bone Research | Wheaton | Maryland | United States | 20902 |
| 8 | Shelby Clinical Research, LLC | Shelby | North Carolina | United States | 28150 |
| 9 | Altoona Center for Clinical Research | Duncansville | Pennsylvania | United States | 16635 |
| 10 | Biopharma Informatic, LLC | Houston | Texas | United States | 77043 |
| 11 | Arthritis Clinic: Western Washington Medical Group | Bothell | Washington | United States | 98021 |
| 12 | Arthritis Northwest PLLC | Spokane | Washington | United States | 99204 |
Sponsors and Collaborators
- Horizon Therapeutics Ireland DAC
Investigators
- Study Director: Supra Verma, MD, Horizon Therapeutics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HZNP-KRY-408